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1. Introduction  
Chronic Myeloid Leukemia (CML) appears as a consequence of the reciprocal translocation 
between chromosomes 9 and 22 which results in the expression of the Bcr-Abl oncoprotein 
in a hematopoietic stem cell. The tyrosine kinase activity of Bcr-Abl is the direct cause of the 
disease. Therefore, inhibitors of this kinase activity are being used in the treatment of CML. 
Imatinib was the first of such inhibitors and is the first line treatment in CML. However, the 
appearance of Bcr-Abl mutants that are resistant to these inhibitors has emerged as a 
problem in the treatment of CML. Consequently, the search for new drugs or therapeutic 
targets is underway. 
The proteasome is a multiprotein complex where proteins are degraded in a much regulated 
manner. Protein degradation at the proteasome is dependent upon ubiquitylation, which, in 
turn, is mediated by ubiquitin-ligase complexes. By degrading specific proteins, the 
proteasome is involved in cellular processes as important as cell cycle regulation, 
proliferation, differentiation and survival. As such, its activity is also related to the 
transformation of tumor cells. In fact, it has been shown that tumor cells show an increase in 
proteasome activity. Specifically, Bcr-Abl tyrosine kinase activity results in an increase of 
proteasome activity and degradation of some negative regulators of cell cycle progression as 
p27kip1. Therefore, proteasome inhibitors could be an alternative in CML treatment.  
In this chapter, we will discuss the available data suggesting that proteasome inhibition 
could be used in the treatment of CML, including those cases in which Bcr-Abl inhibition is 
not a possibility. 
2. Bcr-Abl and its control of the cell cycle and apoptosis 
In the t(9;22)(q34;q11) translocation found in CML, the bcr (Breakpoint Cluster Region) and 
abl (Abelson Leukemia) genes get fused. As a result, the chimeric tyrosine kinase 
oncoprotein Bcr-Abl is expressed (Ben-Neriah et al., 1986). Unlike c-Abl that shuttles 
between the nucleus and the cytoplasm and whose kinase activity is finely tuned, Bcr-Abl is 
cytoplasmic and its kinase activity is increased and deregulated (Salesse & Verfaillie, 2002). 
Through phosphorylation of different substrates, Bcr-Abl activates different signal 
transduction pathways that participate in the control of cellular proliferation, differentiation, 
migration, adhesion and survival (Afar et al., 1994; Andreu et al., 2005; Bedi et al., 1994; 
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Gordon et al., 1987; Horita et al., 2000; Jiang et al., 2000; Puil et al., 1994; Salesse & Verfaillie, 
2003; Sawyers, 1993). 
Several different substrates and partners of Bcr-Abl have been identified so far. Current 
efforts are directed at linking these pathways to the specific pathologic defects that 
characterize CML. These defects include increased proliferation and/or decreased apoptosis 
of a hematopoietic stem cell or progenitor cell (which leads to a massive increase in myeloid 
cell numbers), premature release of immature myeloid cells into the circulation (probably 
due to a defect in adherence of myeloid progenitors to marrow stroma) and genetic 
instability which results in disease progression (Druker, 2008).  
Pathways activated by Bcr-Abl include the Ras-Raf-MAPK, the PI3K/Akt and the 
JAK/STAT pathways. The Ras-Raf-MAPK pathway links Bcr-Abl to the increased 
proliferative rate. The PI3K/Akt pathway induces survival signals through different 
mechanisms such as the Ras-Raf pathway, the phosphorylation of Bad, the induction of Bcl-
xL expression and the inhibition of caspase activity. Besides, it controls the activity of several 
transcription factors involved in the expression of cell cycle regulatory proteins, such as 
FoxO, belonging to the Forkhead family of transcription factors, and NF-κB (Manning & 
Cantley, 2007; Medema et al., 2000). Akt also regulates cell growth through mTOR and the 
control of protein translation and synthesis (Manning & Cantley, 2007). The JAK/STAT 
pathway is also a target of Bcr-Abl kinase activity. Bcr-Abl induces the expression of the 
antiapoptotic protein Bcl-xL through the activation of STAT5, which binds to the promoter 
of the bcl-xL gene, thus increasing survival of Bcr-Abl expressing cells (Horita et al., 2000). 
Bcr-Abl regulates the expression and activity of the cell cycle inhibitor p27kip1 through the 
PI3K/Akt pathway. The inhibition of Bcr-Abl and the inhibition of the PI3K/Akt pathway 
both result in an increase of p27kip1 levels. Bcr-Abl also induces the expression of cyclins D 
and E and the activity of the cyclin E associated kinase Cdk2, resulting in the 
phosphorylation and inactivation of the tumor suppressor Retinoblastoma protein (Rb). 
Consequently, Bcr-Abl expressing cells show a deregulation of one of the main mechanisms 
controlling cell cycle progression along G1 and into S phase (Andreu et al., 2005).  
Therefore, by activating several different signal transduction pathways, Bcr-Abl induces cell 
proliferation and suppresses apoptosis in CML cells. 
3. The proteasome as a therapeutic target 
Protein synthesis and degradation are key mechanisms by which protein levels are 
regulated inside cells. In fact, specific protein degradation has emerged as a very active field 
of research. Two different machineries are involved in this process: the autophagosome 
(which will not be considered in this chapter) and the proteasome. 
3.1 Protein degradation at the proteasome 
The 26S proteasome is a multiprotein complex that can be found in the cytoplasm and in the 
nucleus of eukaryotic cells. It is composed of a catalytic 20S core and two 19S regulatory 
subunits. Proteasome assembly and protein degradation are both ATP dependent (Almond 
& Cohen, 2002; Baumeister et al., 1997; Baumeister et al., 1998). The catalytic core has three 
activities: chymotryptic, tryptic, and post-glutamyl peptide hydrolytic-like activities.The 
regulatory subunits are responsible for substrate recognition and unfolding. The proteasome 
is involved in a wide variety of cellular processes including apoptosis, cell cycle and 
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division, differentiation and development, all of them related directly or indirectly to 
tumoral transformation (DeSalle & Pagano, 2001). 
For a protein to be degraded at the proteasome, it must be labelled with ubiquitin. Ubiquitin 
is a small polypeptide of 76 aminoacids which is highly conserved in all eukaryotes. Protein 
ubiquitylation not only can lead to degradation but is also a mechanism involved in 
intracellular transport. Ubiquitin can be added to proteins as single molecules to one 
(monoubiquitylation) or several (multiubiquitylation) Lysine residues or as polyubiquitin 
chains (polyubiquitylation) using one of several Lysine residues of the ubiquitin molecule to 
form the chain. 
Ubiquitylation requires the sequential activity of three enzymes. The C-terminal Glycine of 
ubiquitin is activated in an ATP dependent process by an E1 ubiquitin-activating enzyme. 
This reaction results in the formation of a thioester covalent linkage between ubiquitin and a 
Cysteine residue in E1. Activated ubiquitin is then transferred to the ubiquitin-conjugating 
enzyme E2 by a trans-esterification reaction. Finally, a ubiquitin-ligase E3 enzyme transfers 
the ubiquitin molecule to the specific target protein to be degraded, thus acting as the 
substrate recognizing enzyme. This conserved ubiquitylation cascade allows for different 
combinations of E1-E2-E3 molecules leading to the recognition, labeling and degradation of 
multiple target proteins (Hershko & Ciechanover, 1998). 
3.2 The proteasome and the cell cycle control 
Along the cell cycle, two different E3 complexes are involved in the degradation of 
regulatory proteins. The SCF complex contains four different subunits: Skp1, Cul1, 
Roc1/Rbx1 and one of several different F-box proteins. This E3 complex is necessary, for 
instance, for the degradation of G1 cyclins, leading to the G1/S transition. G2 cyclins, on the 
other hand, are ubiquitylated by the E3 APC/C (Anaphase Promoting 
Complex/Cyclosome). The APC/C complex is activated by phosphorylation and its activity 
is required for mitosis (Murray, 2004). 
The F-box protein in the SCF complexes interacts with specific substrates targeting them for 
degradation. Interaction with Skp1 requires the conserved F-box region. The substrate that 
is to be degraded needs to be previously phosphorylated. SCF complexes containing the F-
box protein ǃ-Trcp (SCFǃ-Trcp) are involved in the degradation of proteins of the NF-κB 
pathway and of ǃ-catenin. Another important F-box protein is Skp2 (S-phase kinase-
interacting protein 2), identified as a protein interacting with cyclin A/Cdk2 complexes 
(Zhang et al., 1995). Many key regulators of the cell cycle, including the cell cycle inhibitor 
p27kip1, are ubiquitylated by SCFSkp2 complexes (Carrano et al., 1999; Sutterluty et al., 1999; 
Tsvetkov et al., 1999). 
The cell cycle inhibitor p27kip1 binds to Cdk2-containing complexes, inhibiting its kinase 
activity and therefore blocking cell cycle progression along G1 and into the S phase. It can 
also bind to cyclin D-containing complexes, where p27kip1 is “sequestered” and maintained 
away from active cyclin E/Cdk2 complexes (Bouchard et al., 1999; Perez-Roger et al., 1999). 
p27kip1 levels in tumors are useful as a prognostic marker. Degradation of p27kip1 at the 
proteasome requires its previous phosphorylation (at Threonine 187) by the same cyclin 
E/Cdk2 complexes it inhibits. Next, the SCFSkp2 complex recognizes the phosphorylated 
protein and labels it with a polyubiquitin chain leading to its degradation (Carrano et al., 
1999; Montagnoli et al., 1999; Nguyen et al., 1999; Perez-Roger et al., 1999; Perez-Roger et al., 
1997; Sheaff et al., 1997; Sutterluty et al., 1999; Tsvetkov et al., 1999; Vlach et al., 1997). 
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Skp2 expression changes along the cell cycle, being higher in S and G2 and lower in M and 
G1. Induction of Skp2 in the G1-S transition promotes the degradation of p27kip1, allowing 
cell cycle progression (Andreu et al., 2005; Carrano et al., 1999; Marti et al., 1999; Schneider 
et al., 2006; Wirbelauer et al., 2000; Zhang et al., 1995). Skp2 is degraded at the proteasome in 
mitosis, when the APC/C complex becomes active (Wirbelauer et al., 2000). Ectopic 
expression of Skp2 in quiescent cells is sufficient to induce cell cycle entry, making Skp2 a 
potent oncoprotein. In many tumors, the levels of Skp2 and of p27kip1 are inversely 
proportional: low Skp2 correlates with high p27kip1 and slow growing tumors, whereas high 
Skp2 correlates with low p27kip1 and fast growing tumors. 
3.3 Proteasome inhibition: Bortezomib 
The relationship between the ubiquitin-proteasome system (UPS) and the regulation of 
cellular proliferation, differentiation, survival and transformation led to considering the 
proteasome as a suitable target in cancer therapy (Adams, 2004). Proteasome inhibitors 
block protein degradation, causing the accumulation of damaged proteins and inducing the 
heat shock response and cell death (Concannon et al., 2007; Friedman & Xue, 2004).  
Among the several proteasome inhibitors described, Bortezomib has been approved by the 
FDA for treatment of Multiple Myeloma and Mantle Cell Lymphoma (Ocio et al., 2008; 
Perez-Galan et al., 2006). Bortezomib is a dipeptdyl boronic acid that inhibits specifically 
and reversibly the chymotrypsine like activity of the proteasome, thought to be the rate 
limiting step of proteasome degradation (Eldridge & O'Brien, 2010; Jung et al., 2004; 
Richardson et al., 2006).  
Surprisingly, Bortezomib appears to be quite selective against tumor cells. For some reason, 
normal cells seem to be more resistant to proteasome inhibition. One of the molecular effects 
of Bortezomib in several (but not all) cell types is the inhibition of the NF-κB pathway 
involved in suppressing apoptosis and increasing cell survival and resistance to cytotoxic 
agents (Baud & Karin, 2009). Some cases of Multiple Myeloma show an increase in NF-κB 
signaling making them especially sensitive to Bortezomib. Other probably important targets 
of Bortezomib are p53, p21, p27, Bax, Smac/Diablo and p44/42MAPK, all of them involved 
in the regulation of cell proliferation and/or survival (Voorhees et al., 2003). 
4. Inhibition of the proteasome in CML 
Proteasome activity is necessary for all cells to maintain the appropriate balance between 
protein synthesis and degradation. Therefore, proteasome inhibitors have a highly cytotoxic 
effect. However, cancer cells seem to be more sensitive to proteasome inhibition than control 
or normal cells.  
4.1 Bcr-Abl and the proteasome 
Bcr-Abl activity down-regulates the level of the cell cycle inhibitor p27kip1 in different cell 
models expressing Bcr-Abl endogenously (like K562) or exogenously (like Mo7e and BaF/3) 
and in primary CML CD34+ cells. Moreover, exogenous p27kip1 expression partially 
antagonizes the effect of Bcr-Abl on proliferation (Albero et al., 2010; Andreu et al., 2005; 
Bretones et al., 2011; Jonuleit et al., 2000). By inhibiting the tyrosine kinase activity of Bcr-
Abl with Imatinib, the half-life of p27kip1 is increased, meaning that Bcr-Abl induces the 
degradation of p27kip1. At the same time, the expression of Skp2 decreases and when the 
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expression of Skp2 is silenced in Bcr-Abl expressing cells, the levels of p27kip1 increase, 
showing again the inverse relationship between these two proteins. The regulation of p27kip1 
expression by Bcr-Abl depends mainly on the PI3K/Akt pathway. This can be demonstrated 
because when cells are treated with either the Bcr-Abl inhibitor Imatinib or the PI3K 
inhibitor LY294002 the effects are quite similar. These effects are threefold (Fig. 1): first, Akt 
phosphorylates and inactivates FoxO transcription factors, involved in the regulation of 
p27kip1 gene transcription; second, Bcr-Abl induces the expression of Skp2 through the Akt 
pathway, which results in the proteasomal degradation of p27kip1 (Andreu et al., 2005); third, 
Akt also phosphorylates p27kip1 directly, preventing its translocation to the nucleus where it 
inhibits the cyclin/Cdk complexes controlling the cell cycle (Liang et al., 2002). 
 
 
Fig. 1. Bcr-Abl regulation of the level and activity of p27kip1 includes transcriptional 
inhibition, misslocalization and proteasomal degradation. 
Apart from the regulation of key proteins controlling cell cycle progression, there is a direct 
relationship between Bcr-Abl and the proteasome. Exogenous expression of Bcr-Abl in cells 
directly increases the activity of the proteasome and siRNA knock down of Bcr-Abl 
expression in K562 cells is associated with a decrease of all three proteasome activities 
(Crawford et al., 2009). 
As Bcr-Abl regulates the activity of the proteasome and induces the proteasomal 
degradation of several proteins, Bortezomib was proposed as a therapeutic alternative to 
Imatinib, especially in CML cases of Imatinib resistance.  
4.2 Molecular changes in CML cells treated with Bortezomib 
Proteasome inhibition with Bortezomib in Bcr-Abl expressing cell models or primary CD34+ 
cells from CML patients results in a cell cycle inhibition and induction of apoptosis (Albero 
et al., 2010; Gatto et al., 2003; Jagani et al., 2009). Different key regulators are affected by 
Bortezomib leading to the detection of apoptosis markers, such as the activation (cleavage) 
of caspases (3, 8 and 9), or the down-regulation of Bcl-xL and induction of Bim. Among these 
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key events, Bortezomib treatment reverses the Bcr-Abl suppression of FoxO proteins and 
blocks the activation of NF-κB. 
Although apoptosis induction is a commonplace of Bortezomib treatment, the inhibition of the 
cell cycle can be at the G1/S transition or at the G2/M boundary, depending on the cell 
models used (Albero et al., 2010; Gatto et al., 2003). The cell cycle inhibition at the G1/S 
transition can be explained by the accumulation of p27kip1 in Bortezomib treated cells (Fig. 2). 
This accumulation inhibits the kinase activity of cyclin/Cdk complexes, which results in the 
dephosphorylation (activation) of Rb, blocking the cell cycle at the restriction point by the 
sequestration and inactivation of E2F transcription factors. The dephosphorylation of Rb is 
followed by its caspase-dependent processing and degradation, something associated with the 
induction of apoptosis. As a consequence of the impact on Rb phosphorylation, Bortezomib 
treatment also results in the down-regulation of cyclin A expression (Albero et al., 2010).  
In cell lines derived from CML patients in blast crisis, Bortezomib induces the accumulation 
of IκBǂ, correlating with a decrease in the NF-κB DNA binding activity in the nucleus at the 
same time (Gatto et al., 2003). However, this effect was only transient and perhaps does not 
explain the cellular effects of Bortezomib. In contrast, in Baf/3-derived cell lines 
exogenously expressing Bcr-Abl, there was no effect of Bortezomib on NF-κB activity 
(Albero et al., 2010). However, in this same study, the non-canonical NF-κB pathway was 
analyzed and the results show that Bortezomib prevents the activation of NF-κB2. This 
protein is activated by proteolysis from a 100 kDa precursor to yield the 52 kDa active form 
in a proteasome dependent manner (Barre & Perkins, 2007). As NF-κB2 is not activated, the 
expression of two of its regulated targets, Skp2 and Myc, is also inhibited (Albero et al., 
2010; Barre & Perkins, 2007; Schneider et al., 2006). This effect, in turn, would reinforce the 
effect of Bortezomib on the accumulation of p27kip1 (Fig. 2) leading to the dephosphorylation 
of Rb and the cell cycle inhibition at the G1/S transition (Albero et al., 2010). 
 
 
Fig. 2. Possible molecular mechanism leading to cell cycle arrest in G1 and apoptosis in CML 
cells treated with Bortezomib, as proposed (Albero et al., 2010). 
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4.3 Effect of Bortezomib on Imatinib resistant CML cells 
As Bortezomib inhibition of the cell cycle and induction of apoptosis is independent of Bcr-
Abl kinase activity it should be effective even in Imatinib resistant cases. Several different 
reports show the effect of Bortezomib on cells resistant to Imatinib, using cell lines 
exogenously expressing wild type and mutant forms of Bcr-Abl, primary CD34+ cells and 
cell lines derived from patients in blast crisis resistant to Imatinib, or CML cell lines selected 
for Imatinib resistance by chronic exposure to the inhibitor. In all these cases, Bortezomib 
induces apoptosis of Bcr-Abl expressing cells regardless of the mutational status of the 
protein, and at concentrations at which control cells are not sensitive (Albero et al., 2010; 
Colado et al., 2008; Crawford et al., 2009; Gatto et al., 2003; Heaney et al., 2010; Jagani et al., 
2009). As these studies include the highly resistant gate keeper mutant T315I, it is clear that 
Bortezomib could be an alternative to Imatinib when this treatment is ineffective. 
Another source of Imatinib resistant cells is the population of primitive, quiescent 
hematopoietic CML stem cells (Graham et al., 2002). During Imatinib treatment, there is an 
initial phase in which Bcr-Abl transcripts decrease rapidly, followed by a second phase in 
which this decrease is slower. This is probably due to the different sensitivity of CML cell 
subpopulations to Imatinib. Differentiated cells are more sensitive to Imatinib, whereas 
primitive CML stem cells are less sensitive to Imatinib. This difference could be due to the 
almost quiescent state of CML stem cells. This subpopulation of cells (Lin-CD34+) 
represents approximately 0.5% of the CD34+ cells but are likely to be responsible for the 
minimal residual disease found in Imatinib treated patients and to relapse if the treatment is 
interrupted. It is estimated that up to 106 lekemia cells may remain in patients with no 
detectable Bcr-Abl transcripts and therefore it is recommended that Imatinib treatment is 
not interrupted (Bhatia et al., 2003; Graham et al., 2002; Holyoake et al., 1999; Holyoake et 
al., 2001; Quintas-Cardama et al., 2009).  
Bortezomib is also effective against the quiescent CML stem cells in different assays (Heaney 
et al., 2010). Bortezomib treatment induces apoptosis of CD34+ cells from chronic phase 
CML patients at diagnosis, with the accumulation of ubiquitylated proteins but with no 
effect on the kinase activity of Bcr-Abl. The primitive CD34+CD38- population that includes 
the quiescent CML stem cells is also sensitive to Bortezomib, which reduces the long-term 
colony formation capability of the cells. Finally, Bortezomib treatment also leads to a 
significant reduction in the engraftment potential of human CD34+ CML cells, although in 
this experiment there were still detectable Bcr-Abl positive cells. However, the effect of 
Bortezomib is not specific for CML cells, as it induces apoptosis also in normal CD34+CD38- 
hematopoietic stem cells (Heaney et al., 2010). 
5. Conclusion 
Imatinib is the first and so far the best example of rational design of anticancer therapeutic 
drugs. However, it is not able to cure and in some cases its efficacy is reduced due to Bcr-
Abl dependent and independent mechanisms of resistance. In this context, the relationship 
between Bcr-Abl and the proteasome is worth exploiting. In fact, the proteasome inhibitor 
Bortezomib has shown its potential in vitro and in animal models. Nevertheless, proteasome 
inhibition is cytotoxic to all cell types. Therefore, the future of Bortezomib and other “non-
specific” inhibitors or drugs may lie in the search for synergies with other “specific” drugs 
aimed to the molecular events characteristic of the tumor. In Chronic Myeloid Leukemia, 
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inhibiting the proteasome with Bortezomib and inhibiting the kinase activity of Bcr-Abl with 
Imatinib or one of the new compounds may prove the right combination to tackle the 
problems of Bcr-Abl mutations and the Imatinib resistant leukemia stem cell. This could be a 
good starting point for this kind of combined therapies in other tumors where the search for 
a “specific” therapy is still ongoing.  
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